Recro Pharma Inc represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Recro Pharma is dedicated to developing and delivering high-quality medications to patients in need. The company's corporate philosophy emphasizes delivering innovative drug solutions that meet the highest standards of safety and efficacy. Recro Pharma is committed to conducting business ethically and maintaining strong relationships with healthcare professionals, patients, and stakeholders. Through its dedication to research and development, Recro Pharma aims to improve patient outcomes and enhance the quality of life for individuals around the world.

Recro Pharma Inc primarily operates in the United States.

Recro Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for its lead product, IV meloxicam, a non-opioid pain management option. They also secured a licensing agreement for IV meloxicam with Baudax Bio Inc and expanded its use to multiple surgical indications. In addition, Recro Pharma Inc successfully completed a Phase III clinical trial for a new treatment option targeting postoperative pain. The company continues to focus on research and development to provide innovative solutions for patients and healthcare professionals. Recro Pharma Inc's achievements highlight their commitment to advancing pain management and improving patient outcomes.

Recro Pharma Inc is a pharmaceutical company with a rich history and background. Established in 2007, the company is based in Malvern, Pennsylvania. Recro Pharma specializes in developing and commercializing innovative therapies for acute care settings. They focus on creating non-opioid pain management solutions, addressing the growing need for safer and more effective alternatives. The company's dedicated team of scientists and researchers work diligently to provide patients with advanced pharmaceutical products. Recro Pharma's commitment to excellence and dedication to improving patient outcomes has earned them a reputable position in the pharmaceutical industry.

The main competitors of Recro Pharma Inc in the market include companies such as Mallinckrodt Pharmaceuticals, Pfizer Inc, and Amneal Pharmaceuticals.

Recro Pharma Inc is primarily active in the pharmaceutical industry.

Recro Pharma Inc operates as a specialty pharmaceutical company. Its business model involves developing and commercializing innovative products for hospital and ambulatory care settings. Recro Pharma focuses on therapies that address pain management, acute care, and other medical needs. By leveraging its expertise in formulation and manufacturing, the company aims to provide advanced solutions to healthcare professionals and patients. With a commitment to delivering high-quality pharmaceuticals, Recro Pharma Inc continues to contribute to the improvement of patient outcomes and enhance medical treatment options.

Societal CDMO의 P/E 비율은 -11.43입니다.

Societal CDMO의 P/S 비율은 1.08입니다.

Societal CDMO에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Societal CDMO 매출은 96.82 백만 USD입니다.

예상되는 Societal CDMO 이익은 -9.16 백만 USD입니다.

Recro Pharma Inc. is a biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative drugs to improve the health and well-being of patients worldwide. The company has three main divisions: Acute Care, Contract Development and Manufacturing Organization (CDMO), and Healthcare. Within the Acute Care division, the company has a portfolio of pain treatment drugs, including intravenous (IV) acetaminophen injections, methoxyflurane inhalers, and sublingual sufentanil tablets. The CDMO division offers manufacturing services for customers in the biotechnology and pharmaceutical industries. These services include process development and optimization, clinical and commercial manufacturing, stability studies, and quality assurance services. Recro Pharma's Healthcare division focuses on developing products to enhance patient care and safety. For example, the company is currently developing a novel nasal spray for the treatment of severe opioid overdoses. Recro Pharma relies on collaboration with partners and acquisitions of companies that complement its capabilities and processes necessary to create new solutions in the pharmaceutical products and services field. For example, the company was acquired by Alkermes plc in 2015 to acquire specialized formulation expertise and production capacity to complement its own resources. Recro Pharma's business model is based on focusing on continuous improvement of treatment options and patient care through innovative and effective drugs and services that are at the forefront of technology. The company intends to expand its drug development platform through technology partnerships, licensing of intellectual property, and acquisitions of companies to bring future products to market faster and more effectively. Overall, Recro Pharma has become a significant player in the pharmaceutical industry, catering to the needs of physicians, patients, and OEMs worldwide. Recro Pharma offers a wide range of innovative drugs and services that contribute to better healthcare and higher patient satisfaction.

Societal CDMO은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Societal CDMO의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Societal CDMO의 ISIN은 US75629F1093입니다.

Societal CDMO의 WKN은 A1XFAV입니다.

Societal CDMO의 티커는 SCTL입니다.

지난 12개월 동안 Societal CDMO은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Societal CDMO은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Societal CDMO의 현재 배당 수익률은 입니다.

Societal CDMO은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Societal CDMO은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Societal CDMO은 '건강' 섹터에 속합니다.

Societal CDMO의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Societal CDMO는 0 USD를 배당금으로 지급했습니다.

Societal CDMO의 배당금은 USD에 지급됩니다.